Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Childhood Colorectal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: August 27, 2024. Captured 2026-09-09.
Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:
Sources: 1
Primary care physicians.
Pediatric surgeons.
Pathologists.
Pediatric radiation oncologists.
Pediatric medical oncologists and hematologists.
Ophthalmologists.
Rehabilitation specialists.
Pediatric oncology nurses.
Social workers.
Child-life professionals.
Psychologists.
Nutritionists.
For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.
Sources: Supportive and Palliative Care
The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.
Sources: 2 · NCI website
Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3-5] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.
Sources: 3 · 5 · Late Effects of Treatment for Childhood Cancer
Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[6] The U.S. Rare Diseases Act of 2002 defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.
Sources: 6 · Rare Diseases Act of 2002
The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.[7,8] In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:
A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included in the very rare group due to a lack of knowledge and expertise in the management of these tumors.[9]
Sources: 9
The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).[10] These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.[4] Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.
These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.
Information about these tumors may also be found in sources relevant to adults with cancer, such as Colon Cancer Treatment and Rectal Cancer Treatment.
Sources: Colon Cancer Treatment · Rectal Cancer Treatment
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Childhood Colorectal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: August 27, 2024. Captured 2026-09-09.
Most pediatric patients with colorectal cancer present with evidence of metastatic disease,[1] either as gross tumor or as microscopic deposits in lymph nodes, on the surface of the bowel, or on intra-abdominal organs.[2,3]
Treatment options for childhood colorectal cancer include the following:
Surgery.
Sources: Surgery
Radiation therapy and chemotherapy.
Sources: Radiation therapy and chemotherapy
Other agents.
Sources: Other agents
Source: Childhood Colorectal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: August 27, 2024. Captured 2026-09-09.
Complete surgical excision is the most important prognostic factor and the primary goal of surgery, but it is often impossible. Removal of large portions of tumor provides little benefit for those with extensive metastatic disease.[4] Most patients with microscopic metastatic disease generally develop gross metastatic disease. Few individuals with metastatic disease at diagnosis become long-term survivors.
Sources: 4
Source: Childhood Colorectal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: August 27, 2024. Captured 2026-09-09.
Current therapy includes the use of radiation for rectal and lower colon tumors, in conjunction with chemotherapy using fluorouracil (5-FU) with leucovorin.[5] Other agents, including irinotecan, may be of value.[1][Level of evidence C1]
Sources: 5 · 1 · Level of evidence C1
A review of nine clinical trials involving 138 patients younger than 40 years demonstrated that the use of combination chemotherapy improved progression-free survival and overall survival (OS) in these patients. Furthermore, OS and response rates to chemotherapy were similar to those observed in older patients.[6][Level of evidence B4]
Sources: 6 · Level of evidence B4
No significant benefit has been determined for interferon-alfa given in conjunction with 5-FU/leucovorin.[7]
Sources: 7
Source: Childhood Colorectal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: August 27, 2024. Captured 2026-09-09.
No prospective pediatric clinical trials have been conducted using checkpoint inhibitors. However, the U.S. Food and Drug Administration has granted accelerated approval to nivolumab for patients aged 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with combination fluoropyrimidine, oxaliplatin, and irinotecan. This approval was based on extrapolation of the results of the CheckMate 142 trial. The trial showed an objective response rate of 31% and a disease control rate of 69% in patients with MSI-H or mismatch repair deficient colorectal cancers that had progressed after a regimen of fluoropyrimidine, oxaliplatin, and irinotecan.[8]
Sources: CheckMate 142 · 8
Pembrolizumab has also been approved for adult and pediatric patients with unresectable or metastatic MSI-H or mismatch repair deficient cancer, including colorectal cancer that has progressed after fluoropyrimidine, oxaliplatin, and irinotecan therapy. This approval was based on the KEYNOTE-164 trial, which demonstrated an objective response rate of 33% in patients with MSI-H or mismatch repair deficient metastatic colorectal cancer.[9] The approval was also based on the results of the KEYNOTE-117 trial, which included 307 treatment-naive patients with MSI-H or mismatch repair deficient colorectal cancer who were randomly assigned to receive pembrolizumab or a 5-FU–containing regimen. The trial showed that pembrolizumab was superior to chemotherapy, with respect to progression-free survival (median, 16.5 vs. 8.2 months; hazard ratio, 0.60; 95% confidence interval, 0.45–0.80; P = .0002).[10]
Sources: KEYNOTE-164 · 9 · KEYNOTE-117 · 10
Source: Childhood Colorectal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: August 27, 2024. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
Source: Childhood Colorectal Cancer (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Source: Childhood Colorectal Cancer (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
A pediatric oncologist, a doctor who specializes in treating children with cancer, oversees treatment of colorectal cancer. The pediatric oncologist works with other health care providers who are experts in treating children with cancer and also specialize in certain areas of medicine. Other specialists may include:
pediatrician
Sources: pediatrician
pediatric gastroenterologist
Sources: gastroenterologist
pediatric surgeon
Sources: pediatric surgeon
radiation oncologist
Sources: radiation oncologist
pathologist
Sources: pathologist
genetic counselor
Sources: genetic counselor
pediatric nurse specialist
Sources: pediatric nurse specialist
social worker
Sources: social worker
rehabilitation specialist
Sources: rehabilitation specialist
psychologist
Sources: psychologist
child-life specialist
Sources: child-life specialist
There are different types of treatment for children and adolescents with colorectal cancer. You and your child's care team will work together to decide treatment. Many factors will be considered, such as your child's overall health and whether the cancer is newly diagnosed or has come back.
Your child's treatment plan will include information about the cancer, the goals of treatment, treatment options, and the possible side effects. It will be helpful to talk with your child's care team before treatment begins about what to expect. For help every step of the way, visit our booklet, Children with Cancer: A Guide for Parents.
Types of treatment your child might have include:
Source: Childhood Colorectal Cancer (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Surgery to remove the cancer is done if the cancer has not spread to other parts of the body at diagnosis. Learn more about Surgery to Treat Cancer.
Sources: Surgery to Treat Cancer
Source: Childhood Colorectal Cancer (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Colorectal cancer may be treated with external beam radiation therapy. This type of radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Radiation therapy may be given alone or with other treatments, such as chemotherapy.
Learn more about External Beam Radiation Therapy for Cancer and Radiation Therapy Side Effects.
Sources: External Beam Radiation Therapy for Cancer · Radiation Therapy Side Effects
Source: Childhood Colorectal Cancer (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells. Chemotherapy either kills the cancer cells or stops them from dividing. Chemotherapy may be given alone or with other types of treatment, such as radiation therapy.
For colorectal cancer, chemotherapy is taken by mouth or injected into a vein. When given this way, the drugs enter the bloodstream to reach cancer cells throughout the body. Chemotherapy drugs used alone or in combination to treat colorectal cancer in children include:
capecitabine
Sources: capecitabine
fluorouracil (5-FU)
Sources: fluorouracil
irinotecan
Sources: irinotecan
oxaliplatin
Sources: oxaliplatin
Other chemotherapy drugs not listed here may also be used.
To learn more about how chemotherapy works, how it is given, common side effects, and more, visit Chemotherapy to Treat Cancer.
Sources: Chemotherapy to Treat Cancer
Source: Childhood Colorectal Cancer (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Immunotherapy helps a child's immune system fight cancer. Immunotherapy drugs that may be used to treat colorectal cancer include:
nivolumab
Sources: nivolumab
pembrolizumab
Sources: pembrolizumab
Learn more about how immunotherapy works against cancer, how it is given, possible side effects, and more at Immunotherapy to Treat Cancer.
Sources: Immunotherapy to Treat Cancer
Source: Childhood Colorectal Cancer (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
For some children, joining a clinical trial may be an option. There are different types of clinical trials for childhood cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.
You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your child's age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trial search · ClinicalTrials.gov
Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.
Sources: Clinical Trials Information for Patients and Caregivers
Source: Childhood Colorectal Cancer (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment of newly diagnosed colorectal cancer in children may include:
surgery to remove the tumor if it has not spread
radiation therapy and chemotherapy for tumors in the rectum or lower colon
combination chemotherapy, for advanced colorectal cancer
Sources: advanced
Children with certain inherited cancer syndromes may be treated with:
surgery to remove the colon before cancer forms
medicine to decrease the number of polyps in the colon
Sources: medicine
Treatment of colorectal cancer that cannot be removed by surgery, has spread to other parts of the body, or has continued to grow and spread after treatment may include immunotherapy with nivolumab or pembrolizumab. Immunotherapy is only given if your child has certain inherited cancer syndromes or if the cancer has specific gene changes.
If the cancer comes back after treatment, your child's doctor will talk with you about what to expect and possible next steps. There might be treatment options that may shrink the cancer or control its growth. If there are no treatments, your child can receive care to control symptoms from cancer so they can be as comfortable as possible.
Source: Childhood Colorectal Cancer (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Cancer treatments can cause side effects. Which side effects your child might have depends on the type of treatment they receive, the dose, and how their body reacts. Talk with your child's treatment team about which side effects to look for and ways to manage them.
To learn more about side effects that begin during treatment for cancer, visit Side Effects.
Sources: side effects · Side Effects
Problems from cancer treatment that begin 6 months or later after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include:
physical problems
changes in mood, feelings, thinking, learning, or memory
second cancers (new types of cancer) or other problems
Some late effects may be treated or controlled. It is important to talk with your child's doctors about the possible late effects caused by some treatments. Learn more about Late Effects of Treatment for Childhood Cancer.
Carcinoma, Non-Small-Cell Lung
ClinicalTrials.gov recordColorectal Cancer in children and adolescents
Treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no...
1.9 Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater...
In combination with ipilimumab, is indicated for the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or DNA mismatch repair deficient (dMMR), metastatic colorectal cancer that...
• OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)...
In combination with nivolumab, is indicated for the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or DNA mismatch repair deficient (dMMR), metastatic colorectal cancer that...
• Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) as determined by an FDA-authorized test...